[1]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921-927.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(08):921-927.
点击复制

载药微球栓塞治疗在肝癌全程管理中的临床应用进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年08
页码:
921-927
栏目:
综述
出版日期:
2024-08-12

文章信息/Info

Title:
Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma
作者:
吴迪; 郑琳
Author(s):
WU Di; ZHENG Lin.
Department of Interventional Radiology，Affiliated Cancer Hospital of Zhengzhou University（Henan Provincial Cancer Hospital），Zhengzhou，Henan Province 450008，China
关键词:
【关键词】肝细胞癌;  载药微球;  经动脉化疗栓塞术;  介入治疗
文献标志码:
A
摘要:
【摘要】载药微球TACE（DEB-TACE）是应用可加载药物的微球作为栓塞剂，不仅可以永久性栓塞靶血管，而且其加载的化疗药物可缓慢释放，持续作用于靶病灶。近年来，DEB-TACE在肝癌各期的临床治疗中均显示出其重要的作用。对于早期肝癌，DEB-TACE可作为长径＞3 cm、为无法外科切除或消融的富血供肝癌的替代疗法，也可作为肝移植前的桥接治疗。对于早期的大肝癌及有潜在根治机会的中期肝癌，DEB-TACE可快速缩小肿瘤活性区域，后续联合消融治疗有望使患者获得根治。对于不可根治的中晚期肝癌，DEB-TACE联合靶向及免疫药物，三者优势互补，可加强短期疗效、延长患者的生存期。精准DEB-TACE联合HAIC治疗，有望成为中晚期肝癌患者介入治疗的新手段。

参考文献/References:

［1］中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南（2022年版）［J］.中华消化外科杂志，2022，21：143-168.
［2］Zhou M，Wang H，Zeng X，et al.Mortality，morbidity，and risk factors in China and its provinces，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017［J］.Lancet，2019，394：1145-1158.
［3］Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68：394-424.
［4］龚元川，邵国良.载药微球的理化特性及其在肝癌介入治疗中的应用进展［J］.介入放射学杂志，2022，31：616-622.
［5］金泓宇，袁驰，廖明恒，等.载药微球在肝细胞肝癌动脉化疗栓塞治疗中的研究进展［J］.中国普外基础与临床杂志，2020，27：232-238.
［6］Melchiorre F，Patella F，Pescatori L，et al.DEB-TACE：a standard review［J］.Future Oncol，2018，14：2969-2984.
［7］Peng ZY，Cao GH，Hou QM，et al.The comprehensive analysis of efficacy and safety of CalliSpheres drug-eluting beads transarterial chemoembolization in 367 liver cancer patients：a multiple-center，cohort study［J］.Oncol Res，2020，28：249-271.
［8］Lammer J，Malagari K，Vogl T，et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma：results of the PRECISION Ⅴ study［J］.Cardiovasc Intervent Radiol，2010，33：41-52.
［9］郭志，滕皋军，邹英华，等.载药微球治疗原发性和转移性肝癌的技术操作推荐［J］.中华放射学杂志，2019，53：336-340.
［10］Shao G，Zou Y，Lucatelli P，et al.Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization［J］.Ann Transl Med，2021，9：714.
［11］Lencioni R，de Baere T，Burrel M，et al.Transcatheter treatment of hepatocellular carcinoma withdoxorubicin-loaded DC Bead（DEBDOX）：technical recommendations［J］.Cardiovasc Intervent Radiol，2012，35：980-985.
［12］Huo YR，Xiang H，Chan MV，et al.Survival，tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma［J］.J Med Imaging Radiat Oncol，2019，63：802-811.
［13］Yang T，Qin W，Sun X，et al.Efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization using 100-300 μm versus 300-500 μm CalliSpheres microspheres in patients with advanced-stage hepatocellular carcinoma［J］.J Cancer Res Ther，2020，16：1582-1587.
［14］Lee SY，Ou HY，Yu CY，et al.Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma：does size really matter?［J］.Diagn Interv Radiol，2020，26：230-235.
［15］Lee KH，Liapi E，Vossen JA，et al.Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer：evaluation with MR imaging and implication for therapy［J］.J Vasc Interv Radiol，2008，19：1490-1496.
［16］Chang PY，Huang CC，Hung CH，et al.Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment［J］.Liver Cancer，2018，7：312-322.
［17］中国抗癌协会肿瘤介入学专业委员会.药物洗脱微球治疗不可切除原发性肝癌的临床应用共识［J］.中华放射学杂志，2022，56：349-355.
［18］Fu Q，Lv P，Chen Z，et al.Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane［J］.Nanoscale，2015，7：4020-4030.
［19］韦祎，马光辉.尺寸均一微球制剂的研究进展［J］.化工学报，2021，72：6176-6187.
［20］European Association for the Study of the Liver.EASL clinical practice guidelines：management of hepatocellular carcinoma［J］.J Hepatol，2018，69：182-236.
［21］Chang Y，Jeong SW，Young Jang J，et al.Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma［J］.Int J Mol Sci，2020，21：8165.
［22］Kang YJ，Lee BC，Kim JK，et al.Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating Barcelona clinic liver cancer stage 0/a hepatocellular carcinoma［J］.Cardiovasc Intervent Radiol，2020，43：55-64.
［23］Lee IJ，Lee JH，Lee YB，et al.Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients［J］.Ther Adv Med Oncol，2019，11：1758835919866072.
［24］Matsui O，Kobayashi S，Sanada J，et al.Hepatocelluar nodules in liver cirrhosis：hemodynamic evaluation（angiography-assisted CT）with special reference to multi-step hepatocarcinogenesis［J］.Abdom Imaging，2011，36：264-272.
［25］Irie T，Kuramochi M，Takahashi N.Diameter of main tumor feeding artery of a hepatocellular carcinoma：measurement at the entry site into the nodule［J］.Hepatol Res，2016，46：E100-E104.
［26］Razi M，Safiullah S，Gu J，et al.Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma［J］.J Interv Med，2022，5：10-14.
［27］Nicolini A，Martinetti L，Crespi S，et al.Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma［J］.J Vasc Interv Radiol，2010，21：327-332.
［28］Song MJ，Park CH，Kim JD，et al.Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma：a case-control study of Asian patients［J］.Eur J Gastroenterol Hepatol，2011，23：521-527.
［29］Shi Z，Wang D，Kang T，et al.Comparison of CalliSpheres microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients：a randomized controlled trial［J］.Radiol Oncol，2023，57：70-79.
［30］Iezzi R，Pompili M，La Torre MF，et al.Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma［J］.Dig Liver Dis，2015，47：242-248.
［31］Liu J，Zhang W，Lu H，et al.Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs.microwave ablation alone for early stage hepatocellular carcinoma：a preliminary investigation of clinical value［J］.J Cancer Res Clin Oncol，2022，148：1781-1788.
［32］徐鹏程，张庆桥，徐浩，等.CalliSpheres载药微球TACE联合微波消融治疗原发性大肝癌疗效评价［J］.医学影像学杂志，2020，30：620-623.
［33］Cai L，Li H，Guo J，et al.Drug-eluting beads-transarterial chemoembolization plus microwave ablation is an effective and safe treatment strategy in treating hepatocellular carcinoma adjacent to gallbladder［J］.Am J Transl Res，2021，13：7677-7686.
［34］Chung GE，Lee JH，Kim HY，et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein andmay improve the overall survival［J］.Radiology，2011，258：627-634.
［35］Park JW，Chen M，Colombo M，et al.Global patterns of hepatocellular carcinoma management from diagnosis to death：the BRIDGE Study［J］.Liver Int，2015，35：2155-2166.
［36］Zhang Y，Zhang MW，Fan XX，et al.Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma［J］.World J Gastrointest Surg，2020，12：355-368.
［37］Liu F，Chen M，Mei J，et al.Transarterial chemoembolization combined with radiofrequency ablation in the treatment of stage B1 intermediate hepatocellular carcinoma［J］.J Oncol，2019，2019：6298502.
［38］Shi Q，Liu J，Li T，et al.Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria：a single-center propensity score matching analysis［J］.Clin Res Hepatol Gastroenterol，2022，46：101893.
［39］Savic LJ，Chen E，Nezami N，et al.Conventional vs.drug-eluting beads transarterial chemoembolization for unresectable hepatocellular carcinoma：a propensity score weighted comparison of efficacy and safety［J］.Cancers（Basel），2022，14：5847.
［40］Song MJ，Chun HJ，Song DS，et al.Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma［J］.J Hepatol，2012，57：1244-1250.
［41］Lencioni R，Llovet JM，Han G，et al.Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC：The SPACE trial［J］.J Hepatol，2016，64：1090-1098.
［42］Liu J，Xu J，Zhang W，et al.Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma［J］.Acad Radiol，2020，27：704-709.
［43］Xia D，Bai W，Wang E，et al.Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable，advanced hepatocellular carcinoma：a real-world，multicenter，retrospective study［J］.Liver Cancer，2022，11：368-382.
［44］Ren Z，Xu J，Bai Y，et al.Sintilimab plus a bevacizumab biosimilar（IBI305）versus sorafenib in unresectable hepatocellular carcinoma（ORIENT-32）：a randomised，open-label，phase 2–3 study［J］.Lancet Oncol，2021，22：977-990.
［45］Finn RS，Ikeda M，Zhu AX，et al.Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］.J Clin Oncol，2020，38：2960-2970.
［46］石洋.DEB-TACE联合仑伐替尼或PD-1治疗CNLC Ⅱb～Ⅲb期肝细胞癌的近期疗效及预后因素分析［D］.河南：郑州大学2021.
［47］薛怀博，赵国刚，熊永福.肝癌免疫治疗联合靶向治疗的研究进展［J］.临床医学研究与实践，2022，7：191-194，198.
［48］Wang M，Sun L，Han X，et al.The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy［J］.Clin Res Hepatol Gastroenterol，2023，47：102060.
［49］Chang X，Lu X，Guo J，et al.Interventional therapy combined with immune checkpoint inhibitors：emerging opportunities for cancer treatment in the era of immunotherapy［J］.Cancer Treat Rev，2019，74：49-60.
［50］Cheu JW，Wong CC.Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors［J］.Hepatology，2021，74：2264-2276.
［51］Yi C，Chen L，Lin Z，et al.Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC［J］.Hepatology，2021，74：2544-2560.
［52］He M，Li Q，Zou R，et al.Sorafenib plus hepatic arterial infusion of oxaliplatin，fluorouracil，and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion：a randomized clinical trial［J］.JAMA Oncol，2019，5：953-960.
［53］Huang J，Huang W，Zhan M，et al.Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma［J］.J Hepatocell Carcinoma，2021，8：1445-1458.
［54］Wu Y，Zheng S，Zhang Z，et al.Hepatic arterial infusion chemotherapy with oxaliplatin plus raltitrexed as an alternative option in advanced hepatocellular carcinoma patients with failure of，or unsuitability for，transarterial chemoembolization［J］.Medicina（Kaunas），2022，58：1343.

相似文献/References:

[1]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(08):543.
[2]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
　WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC： initial results in 7 patients[J].journal interventional radiology,2017,(08):161.
[3]赵 倩,颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展 [J].介入放射学杂志,2017,(11):1052.
　ZHAO Qian,YAN Zhiping.Transarterial chemoembolization with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(08):1052.
[4]李 鑫,李 臻,李 刚,等.载药微球化疗栓塞治疗下肢梭形细胞肉瘤1例[J].介入放射学杂志,2018,27(02):111.
　LI Xin,LI Zhen,LI Gang,et al.Successful treatment of lower limb spindle cell sarcoma by using chemoembolization with drug- eluting beads： report of one case[J].journal interventional radiology,2018,27(08):111.
[5]于 奇,吴 杰,高 飞,等.载药微球加载贝伐珠单抗治疗难治性实体瘤4例[J].介入放射学杂志,2019,28(01):81.
　YU Qi,WU Jie,GAO Fei,et al.HepaSphere loaded with bevacizumab for the treatment of refractory solid tumors： preliminary results in 4 patients[J].journal interventional radiology,2019,28(08):81.
[6]李亚华,段旭华,韩新巍,等.TACE术中应用三氧化二砷CalliSpheres载药栓塞微球治疗BCLC B期原发性肝癌13例 [J].介入放射学杂志,2019,28(03):232.
　LI Yahua,DUAN Xuhua,HAN Xinwei,et al.TACE by using arsenic trioxide drug- bearing CalliSpheres beads for the treatment of BCLC stage B HCC： preliminary results in 13 patients[J].journal interventional radiology,2019,28(08):232.
[7]翟越,赵 卫,潘文秋,等.TACE联合载药微球治疗肝癌的研究进展[J].介入放射学杂志,2019,28(12):1211.
　ZHAI Yue,ZHAO Wei,PAN Wenqiu,et al.TACE combined with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2019,28(08):1211.
[8]翟 越,潘文秋,赵 卫,等.CalliSpheres联合阿帕替尼治疗肝癌的安全性和有效性[J].介入放射学杂志,2020,29(05):462.
　ZHAI Yue,PAN Wenqiu,ZHAO Wei,et al.The safety and effectiveness of CalliSpheres combined with apatinib for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2020,29(08):462.
[9]荆 霞,徐 圣.Callispheres栓塞后综合征的综合护理模式与常规护理模式比较[J].介入放射学杂志,2020,29(07):722.
　JING Xia,XU Sheng..Comprehensive nursing mode versus routine nursing mode for post- embolization syndrome in HCC patients after DEB- TACE： a comparative study[J].journal interventional radiology,2020,29(08):722.
[10]肖书萍,肖 芳,郑传胜,等.全周期分阶段护理在载药微球治疗肝癌患者中的应用 [J].介入放射学杂志,2020,29(12):1262.
　XIAO Shuping,XIAO Fang,ZHENG Chuansheng,et al.Application of full-cycle phased nursing care in patients with liver cancer receiving drug-loaded microspheres TACE[J].journal interventional radiology,2020,29(08):1262.

备注/Memo

备注/Memo:
（收稿日期：2023-09-04）
（本文编辑：新宇）
更新日期/Last Update: 2024-08-08